Evaluation of the pharmacoDYNAMIC effects of riociguat in subjects with pulmonary hypertension and heart failure with preserved ejection fraction: Study protocol for a randomized controlled trial

Wiener Klinische Wochenschrift

Volumn 128, Issue 23-24, 2016, Pages 882-889

  Mascherbauer, Julia ^a   Grünig, Ekkehard ^b   Halank, Michael ^c   Hohenforst Schmidt, Wolfgang ^d   Kammerlander, Andreas A ^a   Pretsch, Ingrid ^e   Steringer Mascherbauer, Regina ^f   Ulrich, Silvia ^g   Lang, Irene M ^a   Wargenau, Manfred ^h   Frey, Reiner ⁱ   Bonderman, Diana ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d KLINIKUM COBURG   (Germany)

^e UNIVERSITY OF SALZBURG   (Austria)

^f Second Department of Medicine   (Austria)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^h MARCO GmbH and Co KG   (Germany)

ⁱ NONE   (Germany)

Author keywords

Heart failure with preserved ejection fraction; Medical treatment; Pulmonary hypertension

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; PLACEBO; RIOCIGUAT; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; VASODILATOR AGENT;

ADULT; AGED; ALGORITHM; ARTICLE; CONTROLLED STUDY; DIURETIC THERAPY; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; EVALUATION STUDY; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEMODYNAMICS; HUMAN; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; ADOLESCENT; CLINICAL TRIAL; FEMALE; GERMANY; HEART STROKE VOLUME; HYPERTENSION; MALE; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; MIDDLE AGED; PLACEBO EFFECT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; HYPERTENSION; HYPERTENSION, PULMONARY; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PLACEBO EFFECT; PYRAZOLES; PYRIMIDINES; RESEARCH DESIGN; STROKE VOLUME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 84984918497     PISSN: 00435325     EISSN: 16137671     Source Type: Journal    
DOI: 10.1007/s00508-016-1068-8     Document Type: Article

References (20)

1. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787–847.
2. Lam CS, Roger VL, Rodeheffer RJ, Borlaug BA, Enders FT, Redfield MM. Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study. J Am Coll Cardiol. 2009;53:1119–26.
3. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009;30:2493–537.
4. Bonderman D, Ghio S, Felix SB, et al. Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction: a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation. 2013;128:502–11.
5. Ghofrani HA, Galie N, Grimminger F, et al. Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med. 2013;369:330–40.
6. Ghio S, Bonderman D, Felix SB, et al. Left ventricular systolic dysfunction associated with Pulmonary Hypertension riociguat Trial (LEPHT): rationale and design. Eur J Heart Fail. 2012;14:946–53.
7. Bonderman D, Pretsch I, Steringer-Mascherbauer R, et al. Acute hemoDynamic effects of rIociguat in patients with puLmonary hypertension Associated with diasTolic heart failurE (DILATE-1): a randomized, double-blind, placebo-controlled, single-dose study. Chest. 2014;146(5) doi:10.1378/chest.14-0106.
8. Guazzi M, Vicenzi M, Arena R, Guazzi MD. Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1‑year study. Circulation. 2011;124:164–74.
9. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309:1268–77.
10. Pieske B, Butler J, Filippatos G, et al. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014;16(9) doi:10.1002/ejhf.135.
11. Bonderman D, Ghio S, Felix SB, et al. Riociguat for heart failure with secondary pulmonary hypertension: post-hoc analysis of the LEPHT study. Eur Heart J Suppl. 2014;35:385
12. Stasch JP, Evgenov OV. Soluble guanylate cyclase stimulators in pulmonary hypertension. Handb Exp Pharmacol. 2013;218:279–313.
13. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212–5.
14. Sharkovska Y, Kalk P, Lawrenz B, et al. Nitric oxide-independent stimulation of soluble guanylate cyclase reduces organ damage in experimental low-renin and high-renin models. J Hypertens. 2010;28:1666–75.
15. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991;325:1468–75.
16. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–71.
17. Cawley SM, Kolodziej S, Ichinose F, Brouckaert P, Buys ES, Bloch KD. sGC{alpha}1 mediates the negative inotropic effects of NO in cardiac myocytes independent of changes in calcium handling. Am J Physiol Heart Circ Physiol. 2011;301:H157–H163.
18. Ramos-Espiritu LS, Hess KC, Buck J, Levin LR. The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells. J Pharmacol Exp Ther. 2011;338:925–31.
19. Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E. Standardized cardiovascular magnetic resonance (CMR) protocols 2013 update. J Cardiovasc Magn Reson. 2013;15:91.
20. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.